News

Researchers found that adult patients with suspected but unconfirmed HS were more likely to receive symptom-targeted treatment rather than comprehensive disease management.

Clinicians discuss how melanoma gene expression profiling guides sentinel node biopsy choices, refines early-stage risk, and shapes personalized surveillance and oncology referral.

Neal Bhatia, MD, makes the case for photodynamic therapy as a versatile, field-treating option, not just an alternative to surgery.

Emma Guttman-Yassky, MD, PhD, discusses findings from an abrocitinib on-off JADE REGIMEN analysis and what they may mean for disease modification in atopic dermatitis.

This review of the latest dermatological studies includes insights on cross-linked HA for neck wrinkles, dupilumab for eczema molluscatum, 10 ms pulsed dye laser for rosacea, and more.

Australian multicenter data shows older head and neck squamous cell carcinoma patients often miss standard radiotherapy-plus-chemo, yet guideline care boosts survival.

New HS study links prior bariatric surgery to lower pain and depression scores but adjusted results show no clear benefit.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

David Oberlin, MD, FAAD, said the true value of AAD lies in clinicians returning to practice and applying new knowledge to patient care.

Listening to favorite music or white noise during cosmetic botulinum toxin injections eases pain and stress, especially for first-time patients, with simple, low-cost comfort benefits.

In a pilot study, autologous IgG injections show early, lasting symptom and quality-of-life gains in antihistamine-resistant chronic spontaneous urticaria (CSU).

Investigators reported that individualized adalimumab dose adjustments based on serum drug levels could increase clinical response rates compared with standard dosing.

Dermatology Times' editor in chief highlights essential late-breakers from AAD 2026, including rademikibart, KT-621, nemolizumab, and delgocitinib.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Can a Mediterranean diet clear skin, or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Data show that upadacitinib reduces systemic inflammatory burden in AD, including hs-CRP, a biomarker validated as an independent predictor of major cardiovascular events.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Jillian Rork, MD, discusses how Down syndrome is increasingly being understood through the lens of immunology and inflammatory skin disease.

Dutch registry data show obesity and smoking predict higher psoriatic arthritis activity, making weight loss and quitting key to better control.

Learn how a specialized financial partner can enable independent practices to navigate market pressures while expanding access and boosting performance.

New data unveiled at AAD 2026 emphasized the growing role of targeted immune modulation and systemic therapies in dermatologic care.

In this episode, Renata Block, DMSc, MMS, PA-C, and Zachary Rubin, MD, discuss the overlapping worlds of allergy and dermatology—and how better cross-specialty understanding can dramatically improve patient outcomes.

Recent research on orchid-derived skin care reveals antioxidant, anti-inflammatory, and wound-healing potential, but major gaps in clinical proof and safety reporting remain.

Turmeric and curcumin supplements used for hair loss are increasingly associated with rare but serious cases of liver injury.

Cold atmospheric plasma eases stubborn oral lichen planus in long follow-up study, with a new scoring system tracking pain, function, and healing.

A 24-week trial shows ruxolitinib cream sustains control and itch relief in moderate atopic dermatitis when steroids fail, with a positive safety profile.

The analysis highlights potential disease-specific effects of GLP-1 pathway modulation across inflammatory conditions.

A retrospective study of 199 CSU patients found that elevated baseline D-dimer was the only independent predictor of high-dose omalizumab requirement after multivariate adjustment.

A phase 1/2 trial enrolling patients with refractory melanoma is now actively recruiting.